CagriSema 10MG/10MG

• Chemical Name: CagriSema (dual-agonist research peptide blend)
• Active Components:
  • Cagrilintide (amylin analogue)
  • Semaglutide (GLP-1 receptor agonist)
  • (Combined for dual metabolic pathway research)
• Molecular Formulas: Proprietary peptide analogs (individual peptides each have distinct formulas based on sequence)
• Molecular Weights:
  • Cagrilintide: ~4,409 g/mol (as commonly listed for the analog form)
  • Semaglutide: ~4,186 g/mol (typical peptide GLP-1 analog)
• CAS Numbers: Not standardized for the blended research product (individual active peptides have separate registry identifiers)
• Classification: Synthetic research peptide blend (dual GLP-1 and amylin receptor agonist analogs)
• Purity: ≥99 % (HPLC-verified research grade; product certificates often provided with purchase)
• Appearance: White to off-white lyophilized (freeze-dried) powder
• Composition per Vial: 10 mg total peptide blend with equal nominal portions (e.g., ~5 mg cagrilintide + ~5 mg semaglutide) — exact ratio depends on vendor formulation
• Container/Content: Typically supplied as 10 mg lyophilized research blend per vial
• Solubility: Requires reconstitution with sterile or bacteriostatic water before laboratory use; stable when refrigerated after reconstitution
• Storage: Unreconstituted vials stored at –20 °C or cooler; reconstituted solutions kept at 2–8 °C and used per research protocol
• Intended Use: For laboratory research and experimental investigation only; not approved for human or veterinary use or clinical administration.

CagriSema is a high-purity research peptide designed for studies on dual-pathway metabolic signaling, receptor behavior, and compound stability in controlled laboratory settings. For Research Use Only.

• Supports studies on GLP-1 dual-pathway metabolic and receptor activity
• Provides a consistent formulation for controlled experimental models
• Suitable for biochemical and cellular research applications

CagriSema 10MG/10MG is a dual-pathway research peptide built for studies on metabolism and energy balance. It combines two GLP-based analogues, and this helps researchers see how both pathways work together. As a result, scientists can study changes in glucose response, appetite models, and overall metabolic activity. The blend also makes it easier to observe how the two compounds interact in a range of research settings.

Key Research Features:

• Activates GLP-1 and Amylin pathways for metabolic research
• Supports studies on glucose control, appetite models, and energy balance
• Helps test dual-agonist effects in cell and biochemical work

Simple Peptide offers CagriSema 10MG/10MG to support ongoing metabolic and endocrine research. In addition, each vial follows clear quality standards, and we include third-party testing with a Certificate of Analysis so researchers can trust the identity and purity of the material.